Congress and Health Insurance Stock Trades: The $462B Sector Congress Writes the Rules For

$462B

annual federal Medicare Advantage payments to private insurers in 2024, fifty-four percent of total Medicare spending

~50%

share of national Medicaid managed-care enrollment held by the five largest public insurers (Centene, Elevance, UnitedHealth, Molina, CVS-Aetna)

~$1T

Medicaid spending reduction over ten years under the 2025 Big Beautiful Bill (CBO and KFF estimates)

19%

single-session drop in UnitedHealth shares on January 26, 2026, on the proposed Medicare Advantage rate notice

Why health insurance is structurally a federal-policy stock

Most publicly traded sectors have some relationship to the federal government. Defense is the cleanest, where Congress is effectively the only customer (we cover that case in congress and defense stocks). Pharma sits a layer further out: companies have private markets too, but FDA approval and Medicare drug pricing make the federal layer dominant (see congress and pharma trades). Health insurance is closer to defense than to pharma. Five publicly traded conglomerates make the bulk of their margin from federally funded programs. The unit economics, growth rates, and stock prices are all functions of policy decisions in a handful of committee rooms on Capitol Hill and a handful of rule-makings at CMS.

The numbers behind that framing:

Medicare Advantage

32.8 million enrollees in 2024. $462 billion in federal payments to private insurers, representing fifty-four percent of total Medicare spending. The annual CMS rate notice (a single rule that sets payment levels for the following year) is the most important date on every insurer's calendar.

Medicaid managed care

States outsource Medicaid administration to private insurers. Centene leads with 17.7 percent share, Elevance 10.8, UnitedHealth 8.8, Molina 6.3. Together the Big Five run about half of the national Medicaid book. State-by-state contract decisions plus federal funding levels drive revenue.

ACA marketplace

Federal premium tax credits flow through insurers selling on the exchanges. The Inflation Reduction Act expanded those credits through 2025. Their expiry at the end of 2025 triggered an eighteen percent average benchmark-premium hike for 2026 and a forty-three-day government shutdown over their potential extension.

CMS rulemaking

Star ratings, prior-authorization rules, risk-adjustment audits, and the annual MA rate notice are all administrative rules that can move a $400-billion-market-cap stock ten to twenty percent intraday. The rule-makers report to a presidential administration and a congressional oversight structure.

The implication for trade analysis: a member of Congress who can read which way a CMS rule will land, or who participates in writing the legislation that constrains it, has access to information that moves these stocks more reliably than equity-research firms can. Whether any specific member exercises that access is a case-by-case question. The structural opportunity is sector-wide.

The five committees with insurer jurisdiction

Not every committee carries equal weight for this sector. These five have direct authority over the legislation, oversight, and rulemaking that determines insurer revenue and margin.

Senate Finance Committee

Medicare and Medicaid jurisdiction. Chair: Sen. Mike Crapo (R-ID).

Senate Finance has the single broadest reach over insurer revenue. Medicare Advantage payment rates, Medicare Part D drug pricing, Medicaid block-grant proposals, and the policy framework around ACA premium tax credits all originate or pass through this committee. Finance hosted the 2024 Witty hearing on the Change Healthcare cyberattack. Members sit on classified briefings related to insurer cybersecurity, fraud investigations, and program-integrity audits.

House Energy and Commerce, Health Subcommittee

Medicaid, ACA marketplaces, Medicare Part B, drug pricing. Chair: Brett Guthrie (R-KY) full committee; Morgan Griffith (R-VA) Health Subcommittee.

E&C Health writes the Medicaid policy that determines whether Centene and Molina expand or contract. It also handles ACA marketplace legislation and the FDA-CMS coverage interface. The 2025 Big Beautiful Bill Medicaid provisions ran through here in conference, even though the final structure landed in budget reconciliation.

House Ways and Means, Health Subcommittee

Medicare Parts A and B financing. Includes Rep. Kevin Hern (R-OK).

Ways and Means handles the tax-and-spend dimension of Medicare, which is to say most of the funding-side decisions that drive Medicare Advantage payment levels. Hern's December 2025 sale of $250,000 to $500,000 in UnitedHealth via a family trust, while sitting on this subcommittee, is one of the more documented committee-aligned insurer trades of the cycle.

Senate HELP Committee

ACA insurance markets, employer-based coverage, drug approvals. Chair: Sen. Bill Cassidy (R-LA). Members: Sen. Markwayne Mullin (R-OK), Sen. Tommy Tuberville (R-AL).

HELP handles the regulatory side of ACA insurance markets, the FDA confirmation hearings that move pharma-insurer interactions, and employer-side coverage rules. Mullin's February 2026 UnitedHealth purchase ($50,000 to $100,000) and Tuberville's broader healthcare-trading record both attach to HELP membership.

House Oversight

Insurer audits, Medicaid investigations, ACA implementation reviews.

Oversight does not write the rules but it conducts the investigations that flag prior-authorization abuses, denial-rate disparities, and Medicare Advantage marketing violations. Investigations can move stocks both ways, sometimes prompting consent decrees that establish multi-year revenue caps.

Four documented moments where insurer stocks moved on Washington

Each of these is a window where the gap between what a sitting committee member knew and what the broader market knew was unusually wide.

1

Change Healthcare cyberattack and the Witty hearing (Feb-May 2024)

On February 21, 2024, the BlackCat ransomware gang attacked UnitedHealth's Change Healthcare subsidiary, which processes roughly half of all U.S. medical claims. UnitedHealth paid a $22 million bitcoin ransom. The full-year cost ballooned from initial estimates of $872 million to $2.3 to $2.45 billion. UNH was down approximately fifteen percent year-to-date by mid-April. CEO Andrew Witty testified before Senate Finance on May 1, 2024, drawing bipartisan criticism for the security failure. Members of Finance knew the depth of the loss, the ransom payment, and the projected restoration timeline before the public did.

2

The UnitedHealth CEO exit (May 13, 2025)

Witty stepped down "for personal reasons" capping a year that also included the December 2024 killing of UnitedHealthcare CEO Brian Thompson. UNH suspended 2025 guidance. Shares fell roughly eighteen percent in a single session to a four-year low, after a separate twenty-percent drop on April 17, 2025. Year-to-date through May 13: down roughly thirty-eight percent. The exit framed the market backdrop for the Big Beautiful Bill votes two months later.

3

Big Beautiful Bill Medicaid cuts (May-July 2025)

The House passed the One Big Beautiful Bill Act 215-214 on May 22, 2025, and the Senate-amended version 218-214 on July 3. It was signed into law July 4. CBO and KFF scoring put the Medicaid and CHIP spending cut at $911 billion to over $1 trillion over ten years, with projected coverage loss of 10.5 to 11.8 million people by 2034. Centene posted a Q2 loss of $253 million and withdrew its 2025 guidance entirely on July 1. Shares fell approximately forty percent over six months to a decade low near $36. This is also the legislative window in which Rep. Rob Bresnahan sold up to $130,000 across Centene, Elevance, UnitedHealth, and CVS on May 15, seven days before voting yes.

4

ACA subsidy expiry, the 43-day shutdown, and the January MA rate notice (Oct 2025 to Jan 2026)

The enhanced premium tax credits expired at the end of 2025. Democrats made restoration the price of ending a government shutdown that lasted forty-three days, the longest in U.S. history. The final bipartisan deal did not include the enhanced credits. Marketplace insurers had already filed for median eighteen percent premium hikes for 2026. Centene posted a $6.6 billion Q3 writedown reflecting the ACA exposure. Then on January 26, 2026, the Trump CMS proposed a 2027 Medicare Advantage payment increase of just 0.09 percent against analyst expectations of around six percent, plus a 1.53-point cut tied to chart-review diagnoses unlinked to a specific visit. UnitedHealth fell more than nineteen percent in a single session, Humana over twenty percent, CVS thirteen percent.

Five named cases worth knowing

The pattern recurs across both parties, both chambers, and committee versus floor-vote leverage. Each case was disclosed within the 45-day STOCK Act window. None has resulted in an enforcement action.

Rep. Rob Bresnahan (R-PA-08)

Floor vote

The lead case for this editorial. Bresnahan introduced a stock-trading-ban bill (H.R. 3182) on May 6, 2025. Nine days later his account sold up to $130,000 in Centene, Elevance, UnitedHealth, and CVS on May 15. Seven days after that he voted yes on the Big Beautiful Bill Medicaid cut. Centene fell roughly forty percent in the months following. He sits on no committee with insurer jurisdiction, which makes this a floor-vote-timing case, not a committee-leverage case. The full timeline is at our Rob Bresnahan stock tracker.

Rep. Marjorie Taylor Greene (R-GA-14)

Floor vote

Greene bought UnitedHealth on May 14, 2025 ($15,001 to $50,000), again on May 16, 2025 ($1,001 to $15,000), and again on August 4, 2025 ($1,001 to $15,000). The May 14 purchase came the day after UnitedHealth's CEO stepped down and shares fell eighteen percent, and the day before Bresnahan's four-stock sweep. Greene was buying the dip alongside disclosed adds by Buffett and Burry. She is not on a health-jurisdiction committee. The case is interesting because the timing is so different from Bresnahan's: she was buying when he was selling.

Rep. Kevin Hern (R-OK)

Ways and Means Health

Hern sits on the House Ways and Means Health Subcommittee, with direct jurisdiction over Medicare financing. On December 23, 2025 his family revocable trust sold $250,000 to $500,000 of UnitedHealth, marked sell-to-close. Reporting also alleges his office has been late disclosing between $4.2 million and $17.6 million in trades since early 2025. His office disputes the late framing. The position size and the committee assignment together make this one of the cleaner committee-aligned cases.

Sen. Markwayne Mullin (R-OK)

Senate HELP

Mullin sits on the Senate HELP Committee, which handles ACA insurance markets and employer coverage. He purchased UnitedHealth in the $50,001 to $100,000 bracket on February 25, 2026, disclosed March 10. Around the prior holiday period he also bought Eli Lilly, Elevance Health, IQVIA, Intuitive Surgical, and Boston Scientific. Public disclosure aggregators put Mullin's total trading volume since 2023 around $24 million.

Rep. Ro Khanna (D-CA-17)

Spouse trust, no health committee

Khanna does not personally trade. His wife Ritu Khanna's family trust holds the household's investments and includes documented health-insurance positions, among them UnitedHealth in the $51,000 to $115,000 range disclosed in March 2023. The Khanna case is the cleanest spouse-loophole example in the sector: a reform-bill sponsor whose household trust trades the stocks his bills are meant to constrain. The full profile, including the broader 112-percent S&P outperformance, is at our Ro Khanna stock tracker.

A six-factor framework for evaluating a health-insurance trade

Most disclosed trades in this sector are unremarkable. A small number warrant scrutiny. These six factors, used together, separate one from the other.

1. Committee position

Is the member on Senate Finance, House Ways and Means Health, House Energy and Commerce Health, Senate HELP, or House Oversight? Direct insurer oversight makes a trade harder to defend than floor-vote-only proximity.

2. Timing relative to CMS or vote

Trades within two weeks of a Medicare Advantage rate notice, a CMS rulemaking release, a confirmed closed-door briefing, or a major floor vote carry the highest scrutiny. The fourteen-day window is the rough threshold used in academic literature on legislative-information trading.

3. Sector specificity

A broad market ETF is qualitatively different from a four-insurer sweep in a single day. Concentration signals either conviction or information. Bresnahan's four-stock May 15 sale is the recent benchmark.

4. Position size relative to net worth

A $130,000 trade for a $48-million-net-worth member is small in percentage terms but large in disclosure-bracket terms and large in narrative weight. Public reaction tends to track the bracket, not the proportion. Sophisticated analysis should track both.

5. Frequency

One-off versus systematic. Hern's family trust running multi-hundred-thousand-dollar UNH positions is systematic. Greene's three UNH lots over four months are episodic. Bresnahan in 2025 was systematic, then froze to zero in 2026.

6. Personal account vs. spouse or family trust

Spouse-held and family-trust trades have a different ethical profile than direct personal trades, even though they fall within the same STOCK Act disclosure obligation. The legal defense is stronger. The political pressure is roughly the same. The spouse loophole is the deciding question in every active 2025-2026 ban bill.

Frequently asked questions

Because fifty-four percent of Medicare spending and roughly half of Medicaid managed care now flow through a handful of publicly traded conglomerates whose annual margins are reset by single rate notices. The January 2026 Medicare Advantage proposed rate of 0.09 percent (against analyst expectations of around six percent) wiped about twenty percent off UnitedHealth and Humana in one session. There is no comparable single regulatory event for, say, a consumer staples or industrials stock. The sector trades like a policy bond more than like an equity.

Senate Finance Committee (Medicare and Medicaid policy and financing), House Ways and Means Health Subcommittee (Medicare Parts A and B financing), House Energy and Commerce Health Subcommittee (Medicaid, ACA marketplaces, drug pricing), Senate HELP Committee (ACA insurance markets, employer coverage), and House Oversight (insurer audits and investigations). House Financial Services has no direct insurer regulatory authority. The case against Rep. Bresnahan rests on the floor-vote timing, not committee leverage.

No. The closest historical case is Sen. Richard Burr's 2020 sell-off of hospitality and healthcare positions after a closed-door pandemic briefing, which prompted an FBI investigation. The DOJ closed it without charges in 2021. No member of Congress has been criminally convicted under the STOCK Act for trading on congressional information of any kind, in any sector. The standard penalty for a late STOCK Act disclosure is a $200 fine that is waivable. Our editorial on documented insider-trading cases in Congress covers what the enforcement record actually looks like.

Three layered headwinds. First, the Big Beautiful Bill Medicaid cuts (signed July 4, 2025) reduce projected Medicaid spending by roughly $1 trillion over ten years, hitting Centene's core Medicaid managed-care book directly. Second, the post-pandemic Medicaid redetermination has left Centene with a worse-acuity book of remaining enrollees than its rates assumed. Third, the expiration of ACA enhanced premium tax credits at the end of 2025 increases adverse selection on the marketplace business, where Centene is also exposed. The company posted a Q2 2025 loss of $253 million, withdrew 2025 guidance on July 1, and recorded a Q3 $6.6 billion writedown.

Under the 2012 STOCK Act, trading on material non-public information obtained through congressional duties is technically prohibited. In practice, no member has ever been criminally convicted under it. The intent standard is high and the disclosure system is designed to flag activity rather than prosecute it. The cases described on this page were all disclosed within the required 45-day window. They are legal under current law. Whether the disclosure structure satisfies the public's expectation of what a trading ban should accomplish is the open question; the seven active 2025-2026 ban bills are compared in our scorecard.

The disclosure is the starting point. Kapitol.ai is the answer.

Every member. Every sector. Committee context, legislative timing, and a significance score that turns a ticker into a signal.

Start 7-Day Trial for $1

Five companies. Half of Medicaid. Most of Medicare. The rules get written in committee rooms.